Acquired hemophilia A: a single-center study of 165 patients

CONCLUSION: Immunosuppressive therapies yield remarkably high response rates, with a CR rate exceeding 80%; notably, the regimen containing rituximab exhibits a CR rate of approximately 90%. FVIII inhibitor titer of ≥5 BU/mL and BS of ≥6 were poor predictors of CR in patients with AHA.PMID:38433975 | PMC:PMC10907205 | DOI:10.1016/j.rpth.2024.102318

Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Dandan Yu Feng Xue Xiaofan Liu Yunfei Chen Rongfeng Fu Ting Sun Xinyue Dai Mankai Ju Huan Dong Renchi Yang Wei Liu Lei Zhang Source Type: research